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Abstract
Chronic morphine treatment produces profound and long-lasting changes in the pituitary-adrenal
responses to stressful stimuli. The purpose of the present study was to explore the mechanisms
involved in these altered stress responses. Chronic morphine administration increased basal plasma
concentrations of corticosterone and adrenocorticotropic hormone (ACTH), which peaked at 36 h
after the ®nal morphine injection and returned to normal levels within 84-h. Whole brain
glucocorticoid receptor protein expression was reduced (approximately 70%) in morphine-treated rats
4-h after the ®nal morphine injection and these levels recovered within 16-h. Twelve hours following
morphine withdrawal, rats displayed normal ACTH, but potentiated and prolonged corticosterone
responses to restraint stress. Both the ACTH and corticosterone responses to restraint in acutely
withdrawn rats were insensitive to dexamethasone. Furthermore, acutely withdrawn rats displayed
reduced ACTH but prolonged corticosterone responses to peripheral corticotropin releasing hormone
(CRH) administration. These ®ndings suggest that the normal ACTH and enhanced corticosterone
responses to stress in acutely withdrawn rats involved decreased sensitivity of negative-feedback
systems to glucocorticoids, reduced pituitary responsivity to CRH, and enhanced sensitivity of the
adrenals to ACTH. Eight days following morphine withdrawal, rats displayed dramatically reduced
ACTH, but normal corticosterone responses to restraint stress. These rats displayed enhanced
sensitivity to dexamethasone and normal pituitary-adrenal responses to CRH. These data suggest
that the reduced ACTH responses to stress in 8-day withdrawal rats involved increased sensitivity
of negative-feedback systems to glucocorticoids as well as reduced CRH and/or AVP function
in response to stress. Taken together, the results of this study illustrate some of the mechanisms
mediating altered stress responsivity in rats that have received chronic morphine treatment.
Epidemiological and clinical studies indicate that stress is
related to the abuse of opioids in humans (1±3). One of the
principal biological responses to stress is the activation of the
hypothalamic-pituitary-adrenal (HPA) axis and it has been
proposed that an atypical responsivity of the HPA axis to
stressors may contribute to drug abuse in humans (4, 5).
Indeed, laboratory studies have shown that chronic morphine
treatment modi®es the HPA responses to stress (6±10) and
that stress-induced alterations of the reinforcing effect of
morphine involve the HPA axis (11, 12).
The effects of acute morphine treatment and acute stress
exposure on HPA activity are similar in rodents. Both stimuli
increase the release of corticotropin releasing hormone
(CRH), which in turn increases adrenocorticotropic hormone
(ACTH) and corticosterone secretion (6, 8, 13±16). Chronic
morphine treatment and chronic exposure to a homotypic
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stressor also have similar effects on the HPA axis, both
resulting in decreased hormonal responses to these stimuli
with repeated exposure (6, 8, 17±19). More recently, we have
shown that not only the hormonal, but also the physio-
logical effects of chronic morphine treatment are compa-
rable to those observed with chronic stress (20). Chronic
morphine treatment reduced body weight, induced thymus
involution, as well as adrenal gland hypertrophy, and
elevated basal corticosterone concentrations, which are all
characteristic responses associated with chronic stress
exposure (20, 21).
We also showed that despite the negative-feedback effects
of increased basal corticosterone concentrations, rats under-
going acute (12-h) morphine withdrawal displayed a poten-
tiated and prolonged corticosterone response to restraint
(20). This enhanced adrenal response to stress in acutely
withdrawn rats is similar to the well characterized facilitated
HPA responses to an acute, novel stressor in chronically
stressed rats (21±24). The exact neurocircuitries involved
in the facilitated responses to an acute, novel stressor in
chronically stressed rats have not been clari®ed yet. How-
ever, a number of physiological changes associated with
chronic stress that might be involved in facilitation include:
(i) enhanced activity of the paraventricular thalamic
nucleus (24); (ii) enhanced activation of CRH neurones in
the paraventricular (PVN) nucleus of the hypothalamus,
in particular those coexpressing arginine vasopressin (AVP)
(25); (iii) reduced pituitary CRH binding sites, but increased
pituitary ACTH content and pituitary responsivity to CRH
(25±29); (iv) increased adrenal sensitivity to ACTH (21, 29);
and (v) reduced hippocampal glucocorticoid receptor (GR)
expression accompanied with decreased sensitivity to the
negative-feedback effects of glucocorticoids (22, 29±33).
In contrast to these facilitated HPA responses, chronic
exposure to some stressors has been shown to result in
attenuated HPA responses to an acute, novel stressor.
Chronic exposure to social stress, social isolation and post-
natal handling have been shown to reduce the HPA responses
to a subsequent novel stressor (34±37). Recently, we have
shown that rats undergoing prolonged morphine with-
drawal (8-day or 16-day) display a similar reduction in the
pituitary-adrenal responses to restraint stress (20). Although
the mechanisms mediating reduced HPA responsiveness in
chronically stressed rats are currently unclear, two of the
primary physiological changes associated with this phe-
nomenon include reduced PVN CRH mRNA expression
and CRH release in response to stress (35, 37, 38), and
increased hippocampal GR expression associated with
enhanced ef®ciency of negative-feedback systems (34).
It remains to be determined if some of the physiological
changes associated with chronic stress exposure are also
involved in the hyper- and hypo-responsiveness of the HPA
axis in rats undergoing acute and chronic morphine with-
drawal, respectively. Therefore, the aim of the present study
was to evaluate some of the potential mechanisms mediating
the facilitated and attenuated HPA responses to an acute,
novel stressor in acute and extended withdrawal in rats.
For this purpose, in acutely and chronically withdrawn rats,
we examined: (i) changes in basal plasma concentrations of
ACTH and corticosterone with chronic morphine treatment
to determine the time course of morphine-induced changes
in basal HPA activity; (ii) the expression of whole brain GR
protein to determine if altered HPA activity in morphine-
treated rats may be related to changes in the expression
of this receptor; (iii) the effect of dexamethasone treatment
on the ACTH and corticosterone responses to restraint stress
to determine the sensitivity of negative-feedback systems to
glucocorticoids; and (iv) the ACTH and corticosterone
responses to peripheral CRH administration to determine
the sensitivity of pituitary corticotrophs to this secretogogue.
Materials and methods
Subjects
Male Sprague-Dawley rats (Harlan Sprague-Dawley Inc., Indianapolis, IN,
USA), weighing 250±350 g at the beginning of experiment, were used. Rats
were housed singly in Plexiglass cages in a room maintained at 20uC, 40±50%
humidity with a 12-h/12-h light/dark cycle (light from 07.00 h to 19.00 h) and
with free access to food and water. Experiments were initiated between 07.00 h
and 07.30 h and each experimental group consisted of 5±10 rats. All
experimental procedures were performed according to the Guidelines of
the Committee on the Care and Use of Laboratory Animals of the Institute
of Laboratory Animal Resources, National Health Council (Department
of Health, Education and Welfare), and were approved by the University of
Michigan Committee on the Use and Care of Animals.
Morphine dependence and withdrawal
On the basis of previous studies, morphine dependency was induced by
subcutaneous injections of morphine (Mallinickrodt Inc., St Louis, MO, USA)
twice daily at 07.00 h and 19.00 h for 16 consecutive days (20, 39, 40). During
the ®rst 10 days, the dose of morphine was increased by 10 mg/kg per
injection each day from 10 to 100 mg/kg per injection, and during the last
6 days rats were maintained on 100 mg/kg per injection (Fig. 1). As a control,
nondependent rats received twice daily s.c. injections of saline for 16 con-
secutive days. There were four experimental groups: (i) nondependent;
(ii) morphine-dependent; (iii) 12-h spontaneous morphine withdrawal; and
(iv) 8-day spontaneous morphine withdrawal. Experiments in nondependent,
morphine-dependent, and 12-h withdrawal rats were carried out on day 17.
Experiments in the 8-day withdrawal group were carried out on day 24, after
16 days of treatment with morphine followed by 7 days of treatment with
saline. On the ®nal day of the experiment, nondependent, 12-h withdrawal and
8-day withdrawal rats received an injection of saline, whereas morphine-
dependent rats received an injection of morphine (100 mg/kg, s.c.). Cessation
of chronic morphine treatment induced a number of behavioural and physical
withdrawal symptoms, including piloerection, ptosis, lacrimation, rhinorrhea,
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Saline injections
FIG. 1. Timeline of experimental procedure.
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Blood sampling and assays
The tip of the tail of each rat (approximately 1 mm) was nicked with a scalpel
no. 10 blade and approximately 240 ml of blood was collected using
heparinized microcapillary pipettes (Fisher Scienti®c, Pittsburgh, PA, USA).
During the blood collection procedure, which lasted less than 2 min, rats were
lightly wrapped in a piece of cloth. This tail nick method allowed rapid and
repeated blood collection without causing either behavioural or hormonal
distress to the rats as evidenced by basal pituitary-adrenal hormone levels
(Fig. 2A,D and Fig. 3A,D), which are within the range previously reported using
either tail nick or decapitation methods (8, 23, 41, 42). Blood samples were
immediately placed on ice until centrifuged at 4000 r.p.m. for 5 min at 4uC.
Thereafter, the plasma was pipetted into 1 ml Cryovials (Fisher Scienti®c) and
stored at x80uC until analysis. ACTH and corticosterone concentrations were
determined using commercially available RIA kits purchased from Nichols
Institute Diagnostics (San Juan Capistrano, CA, USA) and Diagnostic
Products Corporation (Los Angeles, CA, USA), respectively.
Daily basal pituitary-adrenal activity
We have previously shown that basal ACTH and corticosterone concentra-
tions in rats repeatedly treated with saline remain at low levels, whereas basal
corticosterone concentrations are markedly elevated in rats chronically
treated with morphine (20). Therefore, in the present study, daily basal
ACTH and corticosterone concentrations were determined only in morphine-
treated rats. On the initial experimental day, the tip of the tail of each rat was
nicked, and blood was collected to demonstrate basal hormone levels in
nontreated rats. Immediately thereafter, rats received their ®rst morphine
injection. On subsequent days, the clot from the tail nick incision was removed
and blood was collected daily at approximately 07.00 h immediately prior
to morphine (days 1±16) or saline (days 17±24) administration. Daily blood
collection did not alter pituitary-adrenal activity in morphine-treated rats as
evidenced by similar hormone levels on experimental day 17 in rats exposed
to daily blood collection (Fig. 2) and rats naõÈve to this procedure (Fig. 3B,E
and Fig. 4B,E).
Pituitary-adrenal activity in the absence of restraint stress
Plasma ACTH and corticosterone concentrations on the ®nal experimental
day were determined in nondependent, morphine-dependent, 12-h withdrawal









































FIG. 2. Basal plasma adrenocorticotropic hormone and corticosterone
concentrations of rats chronically treated with morphine. Rats received
twice daily injections of increasing doses of morphine (10±100 mg/kg per
injection, s.c.) for the initial 16 days followed by 8 days of twice daily
administration of saline. Blood was collected daily at approximately
07.00 h, immediately before morphine (days 1±16) or saline (days 17±24)
administration. Data are means and SEM (n=5 ±10). *P<0.05 versus



























































FIG. 3. Total cumulative release (area under curve, AUC) of plasma
adrenocorticotropic hormone (ACTH) and corticosterone in the absence
of restraint in vehicle- and morphine-treated rats. (A,B) Showing
total plasma ACTH and corticosterone AUC in: (i) nondependent;
(ii) morphine-dependent; (iii) 12-h withdrawal and (iv) 8-day withdrawal
rats. AUC data re¯ect plasma ACTH and corticosterone release during
a 4-h period after administration of saline (groups 1, 3 and 4) or morphine
(group 2). Data are means and SEM (n=5±6). *P<0.01 and **P<0.001
versus nondependent and 8-day withdrawal groups.
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determination of basal hormone concentrations, rats received an injection
of morphine (morphine-dependent) or saline (nondependent, 12-h or 8-day
withdrawal). Thereafter, the same tail nick incision was used for repeated
blood collection 15, 30, 60, 90, 120 and 240 min after morphine/saline
administration. Plasma hormone concentrations during this period are
depicted as total area under curve (AUC) (Fig. 3). At the end of this blood
collection period, rats in the four treatment groups were decapitated and whole
brains were removed for determination of GR protein expression in the brain.
Brain preparation and extraction of GR from nuclei
Methods used to prepare rat brain for extraction of total GR were
modi®ed based on previous publications (43, 44). Rat brain was homogenized
in one volume of HEV buffer (10 mM Hepes, 1 mM EDTA, 20 mM
sodium orthovanadate, pH 7.5) with an Ultraturrax tissue homogenizer.
The homogenate was then incubated on ice for 15 min with 0.05% SDS
and 1.0% Triton X-100. Thereafter, 200 U/ml of DNAase I (Boehringer-
Mannheim, Mannheim, Germany) was added to the medium and incubated
for 15 min on ice. Finally, NaCl (®nal concentration equal to 0.5 M) was added,
and the incubation on ice was continued for an additional 30 min. The
homogenates were then centrifuged at 100 000 g for 30 min at 4uC, the pellet
was discarded, and the supernatant was used to immunopurify the GR.
GR immunoprecipitation and Western blotting
The GR was immunoadsorbed from 300 ml aliquots of lysate by rotation
for 3 h at 4uC with 10 ml BuGR2 mouse monocolonal antibody (Af®nity
Bioreagents, Golden, CO, USA) prebound to 80 ml of 20% (w/v) protein
A-Sepharose (Sigma, St Louis, MO, USA). Non-immune mouse IgG (Sigma)
was used as a control for nonspeci®cally adsorbed proteins. The immuno-
pellets were washed ®ve times with 1 ml of a buffer containing 20 mM N-tris-
[hydroxymethyl]-methyl-2-aminoethanesulphonic acid, 50 mM NaCl, 4 mM
EDTA, 10% glycerol, 0.02% Nonidet P-40, at pH 7.6. Pellets were boiled in
80 ml of SDS sample buffer with 10% (v/v) b-mercaptoethanol, and proteins
were resolved in a 9% polyacrilamide/SDS gel. Proteins were ®nally electro-
transferred to an Immobilon-P membrane (Millipore, Bedford, MA, USA)
and probed for the GR with 2 mg/ml of BuGR2 antibody. The immunoreactive
protein was visualized after incubation with horseradish peroxidase-
conjugated goat antimouse counter antibody (Sigma). An autoradiograph
was obtained by reincubation of the membrane with 125I-labelled counter
antibody (DuPont/NEN, Boston, MA, USA).
Sensitivity to dexamethasone
The pituitary-adrenal responses to restraint stress were examined in
nondependent, 12-h withdrawal, and 8-day withdrawal rats pretreated with
dexamethasone. After basal blood collection, rats received an injection of
dexamethasone (0.001, 0.01, 0.1 and 1.0 mg/kg, s.c.) or vehicle. Two hours
following dexamethasone/vehicle administration, restraint stress was initiated.
Rats were restrained for 4-h in their home cages by being placed in Plexiglass
restraint tubes (internal diameter 6 cm, Fisher Scienti®c) provided with
numerous air holes to facilitate breathing and heat dissipation. The same tail
nick incision was used for repeated blood collection at 15, 30, 60, 90, 120 and
240 min after initiation of restraint. Dexamethasone (Gensia Pharmaceuticals;
Irvine, CA, USA) was purchased in 10 mg/ml vials and diluted with saline
to the desired concentrations.
Responsivity to corticotropin-releasing hormone
The pituitary-adrenal responses to peripheral CRH administration were
examined in nondependent, 12-h withdrawal and 8-day withdrawal rats. Rats
were habituated to the i.p. injection procedure by receiving once daily
injections of saline i.p. at approximately 07.00 h for seven consecutive days
prior to the experimental day. After basal blood collection, rats received an
injection of CRH (1 or 10 mg/kg, i.p.) or vehicle. The same tail nick incision
was used for repeated blood collection 15, 30, 60, 90, 120 and 240 min after
CRH/vehicle administration. CRH was a generous gift from J. E. Rivier
(Salk Institute; La Jolla, CA, USA).
Data analysis
Plasma ACTH and corticosterone concentrations are shown in raw form
as well as AUC to facilitate comparisons of hormone levels among the
various treatment groups. Both normalized AUC (response above basal
hormone concentrations) and total AUC (response including basal hormone
concentrations) are shown to account for marked differences in basal hormone
concentrations among the various treatment groups. Normalized AUC values
are an estimate of ACTH and corticosterone release relative to basal levels,
whereas total AUC values are an estimate of total ACTH and cortico-
sterone release, including basal concentrations of these hormones. AUC values
were calculated using the trapezoidal rule (45). For the Western blotting
studies, the autoradiographs were scanned and bands were semiquanti®ed by
densitometry.
Statistical analysis
All data are presented as meantSEM. For AUC values, a square root
transformation was utilized to achieve homogeneity of variances. One or
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FIG. 4. Effect of chronic morphine treatment on glucocorticoid receptor
protein levels in the whole brain. Brains were collected 4 h after the
®nal administration of saline (nondependent, 12-h withdrawal and 8-day
withdrawal groups) or morphine (morphine-dependent rats). (A) Showing
a representative Western blot illustrating immunoreactive gluco-
corticoid receptor (GR) from whole brain extracts in nondependent
(lane 1), morphine-dependent (lane 2), 12-h withdrawal (lane 3) and 8-day
withdrawal (lane 4) rats. (B) Showing a quantitative densitometric analysis
of immunoreactive GR protein levels. (C) Showing a representative
Western blot illustrating a-tubulin levels in the extracts. Data are means
and SEM (n=5).
878 Altered HPA axis activity in morphine-treated rats
# 2001 Blackwell Science Ltd, Journal of Neuroendocrinology, 13, 875±886
the Tukey HSD test of signi®cance (P<0.05) were carried out using Statistica
(v. 5.0; Statsoft, Tulsa, OK, USA).
Results
Changes in basal plasma ACTH and corticosterone
concentrations in rats chronically treated with
morphine (Fig. 2)
Chronic morphine treatment signi®cantly altered basal
plasma ACTH and corticosterone concentrations across the
24-day observation period (Fig. 2A,B; both P<0.0001). Three
days after initiation of chronic morphine treatment, basal
plasma concentrations of ACTH and corticosterone had
increased approximately four- and three-fold, respectively
(ACTH: 9.6t3.9 pg/ml on day 1 versus 44.9t9.2 pg/ml
on day 3; corticosterone: 17.2t3.5 ng/ml on day 1 versus
55.5t15.5 ng/ml on day 3). Basal concentrations of ACTH
and corticosterone remained elevated throughout the 16 days
of morphine treatment, and peaked on day 18, 36 h after the
®nal morphine injection. Plasma ACTH and corticosterone
concentrations returned to normal values within 2 days and
3 days after the last morphine injection, respectively.
Importantly, daily blood collection did not alter basal
ACTH and corticosterone levels in morphine-treated rats,
since hormone levels on day 17 in morphine-treated rats
exposed to daily blood collection (Fig. 2) are similar to those
observed in morphine-treated rats naõÈve to this procedure
(Fig. 5B,E and Fig. 6B,E).
Total ACTH and corticosterone release in vehicle- and
morphine-treated rats in the absence of restraint
stress (Fig. 3)
Total ACTH and corticosterone AUC in the absence of
restraint stress were signi®cantly different among non-
dependent, morphine-dependent, 12-h withdrawal and 8-day
withdrawal groups (Fig. 3A,B; both P<0.0001). In morphine-
dependent rats, during the 4-h after morphine (100 mg/kg)
administration, total ACTH and corticosterone release were
markedly elevated compared to nondependent rats that had
received an injection of saline. Similarly, 12-h withdrawal rats
displayed increased total ACTH and corticosterone release
compared to nondependent rats. Furthermore, total ACTH
and corticosterone release were not signi®cantly different
between morphine-dependent rats that had received an
injection of morphine (morphine-dependent) and those that
had received an injection of saline (12-h withdrawal). Eight
days after their last morphine injection, total ACTH and
corticosterone release in morphine-treated rats were similar
to those observed in nondependent rats.
Effect of chronic morphine treatment on GR protein
levels in the rat brain (Fig. 4)
The monoclonal antibody used in the present study
recognized a prominent band at approximately 94 kDa in
all brain preparations, which is consistent with the estimated
molecular mass for rat GR (46). The intensity of the GR
band was markedly different among the nondependent,
morphine-dependent, 12-h withdrawal and 8-day withdrawal
groups (Fig. 4A). In morphine-dependent rats that had
received their last morphine injection 4-h earlier, quantitative
analysis demonstrated a signi®cant decrease (approximately
70%) of immunoreactive GR compared to nondependent
rats that had received a saline injection 4-h earlier (Fig. 4B;
P<0.01). Brain GR levels were not signi®cantly different
between 12-h withdrawal, 8-day withdrawal and non-
dependent rats. Aliquots of brain extracts were immuno-
blotted for a-tubulin to show that equivalent amounts of
extract were immunoadsorbed for GR (Fig. 4C).
Effect of dexamethasone on ACTH and corticosterone
responses to restraint in vehicle- and morphine-treated
rats (Fig. 5)
Pretreatment with dexamethasone signi®cantly and dose-
dependently reduced the ACTH and corticosterone responses
to 4-h restraint in nondependent rats (Fig. 5A,D; both
P<0.001).
Twelve hours after their last morphine injection, basal
ACTH and corticosterone concentrations in morphine-treated
rats were signi®cantly higher than in vehicle-treated rats
(Fig. 5B,E; both P<0.0001). The ACTH response to 4-h
restraint in rats undergoing 12-h withdrawal was similar
to the response observed in nondependent rats. However, the
corticosterone response to restraint was signi®cantly poten-
tiated and prolonged in 12-h withdrawal rats compared to
nondependent rats (P<0.0001). In 12-h withdrawal rats,
restraint-induced increases in ACTH and corticosterone
secretion were not signi®cantly affected by dexamethasone
(0.01±1.0 mg/kg) treatment. Furthermore, the ACTH and
corticosterone responses to restraint in 12-h withdrawal
rats treated with dexamethasone were signi®cantly elevated
compared to similarly treated nondependent rats (both
P<0.0001).
Eight days after their last morphine injection, basal plasma
concentrations of ACTH and corticosterone in morphine-
treated rats were similar to those observed in nondependent
rats (Fig. 5C,F). Despite recovery of normal basal pituitary-
adrenal activity, these rats displayed dramatically reduced
ACTH (P<0.05), but normal corticosterone responses to 4-h
restraint stress compared to nondependent rats. Pretreat-
ment with dexamethasone signi®cantly reduced the ACTH
(P<0.05) and corticosterone (P<0.01) responses to restraint
in 8-day withdrawal rats. Furthermore, the ACTH response to
restraint in 8-day withdrawal rats treated with dexametha-
sone was signi®cantly reduced compared to similarly treated
nondependent rats (P<0.0001), whereas the corticosterone
response to restraint was similar between these two treatment
groups.
Effect of dexamethasone pretreatment on cumulative
release (AUC) of plasma ACTH and corticosterone
in response to 4-hr restraint in vehicle- and
morphine-treated rats (Table 1)
Because basal ACTH and corticosterone varied markedly
among nondependent, 12-h withdrawal, and 8-day
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withdrawal rats, the data were reanalysed and expressed as
normalized and total AUC to facilitate comparisons among
the three treatment groups (Table 1). The effect of dexa-
methasone pretreatment on normalized and total ACTH and
corticosterone concentrations varied markedly among the
three treatment groups (all P<0.0001). Post-hoc analysis
revealed that in nondependent rats, pretreatment with dexa-
methasone (0.01±0.1 mg/kg) signi®cantly reduced normalized
and total ACTH and corticosterone release in response to 4-h
restraint. In 12-h withdrawal rats, normalized and total
ACTH release in response to restraint were similar to that
observed in nondependent rats. However, both normalized
and total corticosterone release in response to restraint
were markedly elevated in 12-h withdrawal rats compared
to nondependent rats. Furthermore, higher doses of dexa-
methasone (0.1±1.0 mg/kg) were necessary to reduce normal-
ized ACTH release in response to restraint in 12-h withdrawal
rats. Additionally, dexamethasone up to a dose of 1 mg/kg
did not affect total ACTH, normalized corticosterone or
total corticosterone release in response to restraint in rats
undergoing 12-h morphine withdrawal. In 8-day withdrawal
rats, total ACTH release in response to 4-h restraint was
markedly reduced compared to nondependent rats. Moreover,
pretreatment with dexamethasone did not affect normalized
and total ACTH release in rats undergoing 8-day morphine
withdrawal. However, in 8-day withdrawal rats, lower doses
of dexamethasone (0.001±0.1 mg/kg) signi®cantly reduced
normalized and total corticosterone release in response to
restraint.
Effect of peripheral CRH administration on ACTH and
corticosterone concentrations in vehicle- and
morphine-treated rats (Fig. 6)
In nondependent rats, i.p. administration of CRH



















































Non-dependent 12-h withdrawal 8-day withdrawal
Vehicle DEX (0.001 mg/kg) DEX (0.01 mg/kg) DEX (0.1 mg/kg) DEX (1.0 mg/kg)
FIG. 5. Effect of dexamethasone on adrenocorticotropic hormone (ACTH) and corticosterone responses to restraint in vehicle- and morphine-treated rats.
Blood was collected before dexamethasone (0, 0.001, 0.01, 0.1, 1.0 mg/kg, s.c.) administration to determine basal (BL) hormone concentrations. Restraint
stress was initiated 2 h after dexamethasone or vehicle injection. (A,B,C) Showing ACTH responses to 4-h restraint in nondependent, 12-h withdrawal and
8-day withdrawal rats, respectively. (D,E,F) Showing plasma corticosterone responses to 4-h restraint in the same treatment groups. Data are means
and SEM (n=5±6).
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and corticosterone concentrations compared to vehicle
control (Fig. 6A,C; both P<0.0001).
In 12-h withdrawal rats, CRH administration also sig-
ni®cantly increased plasma ACTH (P<0.001) and cortico-
sterone (P<0.05) concentrations (Fig. 6B,E). However, in
these rats, CRH only at the dose of 10 mg/kg signi®cantly
increased both ACTH (P<0.001) and corticosterone
(P<0.05) concentrations. Furthermore, the ACTH responses
to CRH were signi®cantly reduced in 12-h withdrawal
rats compared to nondependent rats (treatmentrtime,
P<0.01). In contrast, the corticosterone responses to
CRH were signi®cantly increased in 12-h withdrawal rats
(treatmentrtime, P<0.01).
In 8-day withdrawal rats, CRH administration also sig-
ni®cantly increased plasma ACTH (P<0.0001) and cortico-
sterone (P<0.001) concentrations (Fig. 6B,D). In these rats,
peripheral CRH administration at doses of 1 mg/kg and
10 mg/kg dose-dependently increased plasma ACTH (P<0.05
and P<0.001, respectively) and corticosterone (P<0.05 and
P<0.001, respectively) concentrations. The ACTH and
corticosterone responses to CRH were similar between
8-day withdrawal and nondependent rats.
Cumulative release (AUC) of plasma ACTH and
corticosterone in response to peripheral
CRH administration in vehicle- and
morphine-treated rats (Table 2)
The effect of peripheral CRH administration on normalized
and total ACTH and corticosterone release was signi®cantly
different among the three treatment groups (all P<0.0001).
Post-hoc analysis revealed that in nondependent rats,
peripheral CRH (1±10 mg/kg) administration signi®cantly
elevated both normalized and total ACTH as well as
corticosterone release. However, in 12-h withdrawal rats,
only the higher dose of CRH (10 mg/kg) signi®cantly
increased normalized or total ACTH release. Moreover, in
12-h withdrawal rats, neither 1 mg/kg nor 10 mg/kg CRH
affected total corticosterone release, whereas both doses of
CRH signi®cantly elevated normalized corticosterone release.
Rats undergoing 8-day morphine withdrawal displayed
similar increases in ACTH and corticosterone release in
response to peripheral CRH administration compared to
nondependent rats.
Discussion
The results of the present study support and extend our
previous observations (20) that chronic morphine treatment
has paradoxical effects on the pituitary-adrenal axis, result-
ing in facilitated responses to restraint in rats undergoing
acute (12-h) morphine withdrawal and attenuated responses
in rats undergoing chronic (8-day) morphine withdrawal.
In the present study, we also demonstrated that chronic
morphine treatment resulted in persistent elevation of basal
corticosterone secretion, whereas ACTH secretion was
only slightly increased in morphine-dependent rats. Chronic
corticosterone hypersecretion in morphine-dependent rats was
associated with a marked reduction of whole brain GR
protein levels, which recovered rapidly after the ®nal
morphine injection. Furthermore, the normal ACTH and
exaggerated corticosterone responses to restraint in rats
undergoing acute withdrawal were associated with reduced
sensitivity of negative-feedback systems to glucocorticoids,
reduced pituitary responsitivity to CRH, and enhanced
adrenal sensitivity to ACTH. On the other hand, the reduced
ACTH responses to restraint in rats undergoing chronic
withdrawal were associated with enhanced sensitivity of
negative-feedback systems to circulating glucocorticoids, but
normal pituitary responsivity to CRH.
In the present study, we demonstrated that chronic
morphine treatment resulted in persistent elevation of basal
TABLE 1. Effect of Dexamethasone Pretreatment on Cumulative Release (Area Under Curve, AUC) of Plasma Corticosterone
and Adrenocorticotropic Hormone (ACTH) in Response to 4-h Restraint in Vehicle- and Morphine-Treated Rats.
Treatment
ACTH (pg/min/dl) Corticosterone (ng/min/ml)
Normalized AUC Total AUC Normalized AUC Total AUC
Non-dependent
Restraint+vehicle 25446t8748 35036t8746 91850t12311 122080t15956
+Dex 0.001 9621t3816a 14595t3438 73551t17909 88135t17729
+Dex 0.01 763t1508a 6223t2284a 19812t12015a 33611t10940a
+Dex 0.1 864t859a 2021t369a x1979t1752a 5763t410a
12-h withdrawal
Restraint+vehicle 41206t2607 55182t4407 213709t10619b 347178t8664b
+Dex 0.01 25653t9549b 44225t2414b 194730t14346b 298358t12985b
+Dex 0.1 1049t3317a 30670t4907b 150842t18459b 307609t21512b
+Dex 1.0 6721t7277a 41861t6438c 151623t16888c 323175t15970c
8-day withdrawal
Restraint+vehicle 6730t1793 8451t2711b 82609t10877 91189t11242
+Dex 0.001 4533t2613 8792t3457 11554t7216a,b 21285t5867a,b
+Dex 0.01 x1552t2291 1557t654 9662t6695a 32893t7491a
+Dex 0.1 x3127t2833 1248t618 2256t2131a 14284t2409a
aP<0.05 compared with vehicle pretreatment within the same treatment group. bP<0.05 compared to the same dexamethasone pretreatment in the
nondependent group. cP<0.05 compared to dexamethasone (0.1 mg/kg) pretreatment in the nondependent group.
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FIG. 6. Adrenocorticotropic hormone (ACTH) and corticosterone responses to peripheral corticotropin releasing hormone (CRH) administration in
vehicle- and morphine-treated rats. Blood was collected before CRH (0, 1, 10 mg/kg, i.p.) administration to determine basal (BL) hormone concentrations.
(A,B,C) Showing plasma ACTH responses to peripheral CRH administration in nondependent, 12-h withdrawal and 8-day withdrawal rats, respectively.
(D,E,F) Showing plasma corticosterone responses to exogenous CRH administration in the same treatment groups. Data are means and SEM (n=5±6).
TABLE 2. Cumulative Release (Area Under Curve, AUC) of Plasma Corticosterone and Adrenocorticotropic Hormone (ACTH)
in Response to Peripheral Corticotropin Releasing Hormone (CRH) Administration in Vehicle- and Morphine-Treated Rats.
Treatment
ACTH (pg/min/dl) Corticosterone (ng/min/ml)
Normalized AUC Total AUC Normalized AUC Total AUC
Non-dependent
CRH vehicle x7373t3746 9736t1516 11211t5878 42017t3694
CRH (1 mg/kg) 57057t1578a 96137t20051a 129427t15834a 193707t20871a
CRH (10 mg/kg) 126944t20865a 169023t26276a 178524t4761a 258751t6707a
12-h withdrawal
CRH vehicle 6977t1527 26878t4766 38721t11533 217826t7869b
CRH (1 mg/kg) 18742t4095 52477t9097 98036t13750a 256848t20042
CRH (10 mg/kg) 105209t17386a 157801t25316a 105027t8340a 287457t13696
8-day withdrawal
CRH vehicle 1535t3683 9366t2711 13376t4923 25334t5422
CRH (1 mg/kg) 47860t11417a 67308t14560a 119364t2578a 173201t34686a
CRH (10 mg/kg) 155855t10947a 207285t14325a 185403t6642a 263247t9551a
aP<0.05 compared to vehicle treatment within the same treatment group. bP<0.05 compared to the same CRH treatment in the nondependent group.
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plasma corticosterone concentrations to approximately 10
times the levels observed in vehicle-treated rats. However,
other studies have shown that basal corticosterone concen-
trations are normal in morphine-dependent rats (8, 9).
This discrepancy is likely due to procedural differences in
the induction of morphine dependence. Since basal cortico-
sterone concentrations are also increased in chronically
stressed rats (21, 32, 36), our results suggest that chronic
morphine dependence under our conditions is a chronic
stressor. Despite the marked increase of basal corticosterone
secretion, basal ACTH concentration was only slightly
increased in morphine-treated rats. This ®nding is consistent
with previous observations that basal ACTH concentration is
generally normal in chronically stressed rats (21, 32). None-
theless, we have previously shown that chronic morphine
treatment results in adrenal hypertrophy and thymus
involution, which are both classic signs of chronic ACTH
hypersecretion and chronic stress exposure (20, 21).
HPA axis activity in rats is very tightly regulated by the
negative-feedback effects of circulating corticosterone (47).
Corticosterone regulates HPA axis activity by interacting
with two steroid receptors: mineralocorticoid (MR) and
glucocorticoid (GR) receptors. Because of the higher af®nity
of MR for corticosterone, it has been suggested that MR
modulate HPA activity under trough basal conditions,
whereas GR play a primary role in the regulation of the
diurnal peak of the circadian rhythm as well as the HPA
responses to stress (16, 21, 48). In the present study, we
demonstrated a marked downregulation of whole brain GR
protein levels in morphine-treated rats. Whole brain GR levels
were dramatically reduced 4-h after the ®nal morphine
injection, but had recovered within 16-h after termination
of chronic morphine treatment. Using the ligand binding
technique, Budziszewska et al. (40) similarly reported a
reduction of hippocampal GR, but not MR, density in
morphine-dependent rats that were adrenalectomized. The
technique of receptor extraction with DNAase digestion used
in present study has the advantage of detecting all forms of
GR, in both nuclear and cytosolic compartments of cells in
nonadrenalectomized rats (43, 44). However, using this
technique, we determined GR protein levels within the whole
brain rather than speci®c anatomical loci. Examination of GR
expression within the whole brain may have concealed
changes in GR within speci®c brain regions 16-h after the
®nal morphine injection. Indeed, previous studies have shown
that although chronic elevation of corticosterone concentra-
tion by either repeated stress or exogenous corticosterone
administration reduces GR expression in the brain, this
effect tends to be restricted to the hippocampus (30, 49).
Nonetheless, the marked downregulation of whole brain GR
in morphine-dependent rats closely resembles GR down-
regulation previously reported in chronically stressed rats and
is likely an adaptive response to prolonged corticosterone
hypersecretion.
Despite the negative-feedback effects of elevated basal
corticosterone concentrations, morphine-treated rats dis-
played potentiated and prolonged corticosterone responses
to restraint stress while undergoing acute morphine with-
drawal. This response is similar to the facilitated HPA
responses to an acute, novel stressor in chronically stressed
rats (21±24). Furthermore, the hormonal responses to res-
traint in acutely withdrawn rats were insensitive to the
negative-feedback effects of the synthetic glucocorticoid dexa-
methasone. Dexamethasone is commonly used to examine
the integrity of negative-feedback systems (50±53). However,
the primary site of action for dexamethasone is the pituitary
(54). This could explain the discrepancy that despite reduced
sensitivity to the negative-feedback effects of dexamethasone,
rats undergoing 12-h withdrawal displayed normal whole
brain GR protein expression. Alternatively, as discussed
previously, it is possible that GR expression is reduced within
some brain regions in acutely withdrawn rats, but that this
effect is diluted by examination of the whole brain. With
respect to dexamethasone-sensitivity, rats chronically treated
with morphine again closely resemble chronically stressed
rats, since rats chronically exposed to stress also display
reduced sensitivity to negative-feedback effects of gluco-
corticoids (21, 22, 29, 31, 32). Thus, the facilitated cortico-
sterone responses to restraint stress in acutely withdrawn rats
are at least in part mediated by impaired negative-feedback
systems.
Although acutely withdrawn rats displayed an exagger-
ated corticosterone response to restraint stress, the ACTH
response to restraint was normal in these animals. This
discrepancy between the ACTH and corticosterone responses
to restraint in acutely withdrawn rats suggests that the
adrenals of these rats are more sensitive to ACTH. Indeed, we
have previously reported that acutely withdrawn rats display
markedly increased adrenal gland weights (20). Moreover, our
observation that the corticosterone responses to peripheral
CRH administration were also exaggerated in acutely
withdrawn rats, despite reduced ACTH responses to this
hormone, also suggests enhanced adrenal sensitivity to ACTH
in these rats. In this respect, rats chronically treated with
morphine also resemble chronically stressed rats, since others
have shown that the adrenals of chronically stressed rats are
also enlarged and hyperresponsive to ACTH (21, 29).
The reduced ACTH responses to peripheral CRH admin-
istration in acutely withdrawn rats also suggest reduced
pituitary sensitivity to CRH. Previously, it has been shown
that chronic stress exposure and chronic CRH administra-
tion result in downregulation and desensitization of CRH
receptors in the rat pituitary and brain (27, 28, 55). Recently,
Iredale et al. (56) also showed that CRH-type I receptor
expression is reduced in morphine-dependent rats undergoing
naltrexone-precipitated opioid withdrawal. Thus, reduced
pituitary responses to peripheral CRH administration in
acutely withdrawn rats may be related to CRH receptor
downregulation and/or desensitization, induced by chronic
activation of this receptor system.
Furthermore, we cannot exclude the possibility that
hypothalamic CRH and/or AVP secretion in response to
restraint stress is increased in acutely withdrawn rats. Indeed,
previous studies have demonstrated enhanced activation of
CRH neurones, in particular those coexpressing AVP, in the
PVN of chronically stressed rats (25). There is also evidence
that the expression of CRH and AVP in the PVN and/or their
release into the hypothalamic-pituitary portal circulation
may be increased in morphine-dependent rats undergoing
withdrawal (57±59). Therefore, it is possible that hypothalamic
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CRH and/or AVP function may be enhanced in acutely
withdrawn rats, but that this effect is counteracted
by reduced pituitary sensitivity to CRH, thereby resulting
in an apparently normal ACTH response to restraint in
these animals. Further studies are necessary to directly
examine the neurocircuitry mediating the facilitated stress
response observed in acutely withdrawn rats.
In contrast to the facilitated corticosterone responses
to restraint in acutely withdrawn rats, rats tested 8 days
after morphine withdrawal displayed dramatically attenuated
ACTH responses to restraint stress. Moreover, restraint-
induced increases in corticosterone were more sensitive to
the negative-feedback effects of dexamethasone in these
chronically withdrawn rats. Together, these data suggest that
the reduced stress responses in chronically withdrawn rats
involve enhanced sensitivity of negative-feedback systems to
circulating glucocorticoids. Enhanced ef®ciency of negative-
feedback processes in chronically withdrawn rats may be
related to increased GR expression. Indeed, previous studies
have shown that attenuated HPA responsivity to stress in
handled rats is related to enhanced negative-feedback
sensitivity and increased hippocampal GR expression (34).
In the present study, we did not ®nd evidence for changes in
GR protein expression in the whole brain of chronically
withdrawn rats. However, examination of GR expression
within speci®c brain regions in these animals may reveal new
information.
Although chronically withdrawn rats displayed reduced
ACTH responses to restraint stress, the ACTH and cortico-
sterone responses to peripheral CRH administration were
normal in these animals. These data suggest that the reduced
pituitary responses to restraint stress in chronically withdrawn
rats probably do not involve changes in pituitary CRH
receptor binding sites, or pituitary ACTH stores, but instead
result from decreased hypothalamic function of CRH and/or
AVP in response to restraint. This effect may be in part
related to increased sensitivity of the negative-feedback
systems to circulating glucocorticoids. Alternatively, chronic
exposure to the stress of morphine dependence and the
profound stress associated with withdrawal may have
increased the threshold for activation of the stress axis, such
that greater intensities of psychological and/or physiological
stressors are necessary to activate the HPA axis in these
animals. To our knowledge, the activity of CRH and/or AVP
neurones during prolonged opioid withdrawal has not been
investigated to date. It is possible that adaptive changes in
the CRH and/or AVP systems mediate some of the hypo-
responsivity observed in rats undergoing extended morphine
withdrawal.
The studies presented here have focused on alterations
in HPA activity that potentially mediate the facilitated and
attenuated stress responsivity in rats undergoing acute and
chronic morphine withdrawal, respectively. However,
altered pituitary-adrenal responsivity to stress in these animals
may be indirectly mediated through adaptive changes in other
neurobiological systems. Indeed, previous studies have shown
that chronic exposure to morphine affects noradrenergic
innervation to the PVN (60±62). It remains to be deter-
mined if modi®cations in noradrenergic neurones potentially
modulate CRH and/or AVP function in morphine-treated
rats, thereby in¯uencing pituitary-adrenal secretions under
basal and stress conditions.
Interestingly, HPA function in acutely and chronically
withdrawn rats appears to have common features with the
HPA dysregulation observed in humans suffering from
depression and post-traumatic stress disorder (PTSD),
respectively. Dysregulation of HPA activity in depressed
patients is manifested by cortisol hypersecretion, reduced
sensitivity to the negative-feedback effects of dexamethasone
and blunted ACTH responses to CRH administration (63). In
contrast, PTSD is associated with reduced cortisol secretion
and enhanced sensitivity to the negative-feedback effects of
circulating glucocorticoids (64, 65). Furthermore, epidemiol-
ogical and clinical studies show a high comorbidity between
drug abuse, depression and PTSD (4, 5, 66, 67). However,
it remains to be determined if drug abuse results in the neuro-
biological abnormalities underlying depression and PTSD
(66, 67). The ®nding that chronic morphine treatment induces
withdrawal time-dependent hyper- and hypo-responsivity of
the HPA axis offers an intriguing animal model to study at
least some aspects of drug abuse, depression and PTSD.
In conclusion, we have shown that the normal ACTH
and exaggerated corticosterone responses to restraint in rats
undergoing acute morphine withdrawal involve reduced
sensitivity of negative-feedback systems to circulating gluco-
corticoids, reduced responsivity of the pituitary to CRH
and enhanced adrenal sensitivity to ACTH. Furthermore,
the reduced ACTH and normal corticosterone responses to
restraint in rats undergoing chronic morphine withdrawal
involve enhanced sensitivity of negative-feedback systems
and reduced CRH and/or AVP function. These experiments
shed light not only on changes in HPA activity associated
with chronic opioid dependence, but they may also be relevant
to studies of depression and PTSD.
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